Fig. 5
From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy
Anti-tumor effect of EnanDIM-C in various syngeneic tumor models. 10 mice per group were inoculated s.c. with either Pan02 pancreas (a), MC38 colon (b), B16F10 melanoma (c), or CT26 colon carcinoma (d, e) tumor cells. Established tumors (40–90 mm3, day 3 to day 13) were repeatedly injected with EnanDIM-C or vehicle (i.tu.) (a-d) or with EnanDIM-C or vehicle (s.c.) at the day after tumor inoculation (e). Mean tumor growth + SEM, Kaplan-Meier survival plots and individual tumor growth of all mice are shown from left to right. Mean tumor growth curves are continued until 50% of mice treated with vehicle have been sacrificed. Light blue bar on each x-axis indicates the treatment period. Log-rank analyses: MC38, p < 0.001; B16F10, p < 0.001; CT26 (i.tu), p < 0.05; CT26 (s.c.), p < 0.01